头颈游离皮瓣重建术前静脉铁剂与输血风险回顾性队列研究
本研究回顾性纳入2022年1月至2025年5月接受头颈癌游离皮瓣重建的成人患者324例,其中32例(9.9%)术前接受静脉铁剂,59例(18.2%)术后需输注浓缩红细胞。结论提示短期铁剂补充可能不足以减少输血需求,需更早和/或更全面的贫血优化策略。
要点
- 术前静脉铁剂未独立降低头颈游离皮瓣术后输血风险或输血量。
- 术前血红蛋白较高与输血风险降低独立相关。
- 晚期肿瘤与术后输血风险增加独立相关。
核心结论
- 短期术前静脉铁剂补充可能不足以减少头颈游离皮瓣重建患者的术后输血需求。
研究设计与样本
- 回顾性队列研究,纳入2022年1月至2025年5月在某三级头颈癌中心接受游离皮瓣重建的成人头颈癌患者324例。
主要发现
- 324例中32例(9.9%)术前接受静脉铁剂,59例(18.2%)术后需输注浓缩红细胞。
临床怎么用
- 对头颈游离皮瓣重建患者,不应仅依赖短期术前静脉铁剂来减少术后输血。
- 应关注术前血红蛋白水平及肿瘤分期以评估输血风险。
- 需考虑更早和/或更全面的贫血优化策略。
局限性
- 回顾性队列设计可能存在选择偏倚和混杂。
- 仅纳入转铁蛋白饱和度<20%且接受静脉铁剂的患者进行比较,样本量有限(铁剂组32例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether preoperative intravenous iron infusion is associated with reduced postoperative packed red blood cell (PRBC) transfusion risk and transfusion volume among patients undergoing head and neck free flap reconstruction. STUDY DESIGN: Retrospective cohort study. SETTING: Tertiary head and neck cancer centre. METHODS: Adult patients undergoing free flap reconstruction for head and neck cancer between January 2022 and May 2025 were included. Starting June 2022, patients with baseline hemoglobin <130 g/L underwent routine preoperative transferrin saturation testing. Patients with transferrin saturation <20% who subsequently received preoperative intravenous iron infusion were compared with those who did not. Primary outcome was receipt of postoperative PRBC transfusion. Multivariable logistic regression was used to assess predictors of transfusion. Negative binomial regression was used to model transfusion volume among transfused patients. RESULTS: Among 324 patients, 32 (9.9%) received preoperative intravenous iron and 59 (18.2%) required postoperative PRBC transfusion. Preoperative iron infusion was not independently associated with postoperative transfusion risk (aOR 1.26, 95% CI: 0.51-3.08, P = .62) or with number of PRBC units transfused (aIRR 1.00, 95% CI: 0.41-2.38, P = .997). Higher preoperative hemoglobin was associated with reduced transfusion risk (aOR 0.96 per g/L increase, 95% CI: 0.94-0.98, P < .001), while advanced tumor stage was associated with increased transfusion risk (aOR 2.55, 95% CI: 1.13-5.77, P = .024). These findings were unchanged in sensitivity analysis restricted to patients receiving iron ≥7 days preoperatively. CONCLUSION: Short-term iron repletion alone may be insufficient to mitigate transfusion requirements, highlighting the importance of earlier and/or more comprehensive anemia optimization strategies in this high-risk population.
引用
- Levy BB, Pradhan A, Choudhary L, et al. Preoperative Iron and Blood Transfusions in Head and Neck Free Flap Reconstruction: A Retrospective Cohort Study. Otolaryngol Head Neck Surg. 2026. PMID: 42949235. doi:10.1002/ohn.70492
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。